Clinical Trial Update: A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase Ib study evaluating the combination of RAD001 (everolimus) and Sutent (sunitinib) for renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• RAD001 (everolimus)
• Sutent (sunitinib)

Snippet

Sponsor: Daniel George, MD | Conditions: Renal Cell Carcinoma | Phase 1 | Status: COMPLETED